Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07177183

Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure

The main objective of the study is to determine whether a subnormal serum creatinine value upon admission to the Post-ICU Care Unit predicts the need for prolonged ventilatory support. A parallel objective of the study is to determine whether exogenous in-take of the dietary supplement creatine in patients with subnormal serum creatinine value is associated with a shortened duration of ventilatory support and improved patients outcome.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chronicare Mund s.r.o., Brno, Czechia

Loading trial locations.

About this study

More than 95% of serum creatinine comes from skeletal muscles, where it is formed by non-enzymatic degradation of creatine. Therefore, in patients with normal kidney function, the serum creatinine value closely correlates with muscle mass volume. It is well documented that critically ill patients lose almost 20% of their muscle mass volume during the first 10 days of their stay in the intensive care unit (ICU). At the same time, it is clear that it is from this group of "longer-stay" patients that those who need subsequent intensive care come. From the above, it can be assumed that in some patients admitted to the post-ICU care unit, the admission serum creatinine value may be subnormal due to muscle devastation caused during the stay in the ICU. This assumption was verified by analysing the admission creatinine values in a group of chronically ventilated adult patients admitted to the post-ICU care unit on CHRONICARE GROUP a.s. over five consecutive months. Of the total number of 264 patients, 123 (47%) patients had an admission serum creatinine value in the subnormal range.

Subnormal serum creatinine levels in patients admitted to the post-ICU care unit may have a number of causes, most of which are related to the patient's pre-existing illness, medical interventions in the ICU, or the critical illness itself. It may be related to chronic liver disease (suppressed creatine synthesis) or kidney disease (suppressed creatine synthesis). It may also be a falsely low serum creatinine level caused by fluid overload. Critical illness itself leads to sarcopenia, as a result of which the total amount of creatinine produced in the muscles decreases, and therefore the serum creatinine concentration. Unfortunately, the development of sarcopenia induced by critical illness cannot be influenced therapeutically. Similarly, mitochondrial dysfunction in muscle cells induced by critical illness cannot be influenced therapeutically. This abnormality leads to a decrease in Adenosine Triphosphate (ATP) production and therefore to a decrease in the formation of creatine phosphate, which is the main source for creatinine formation (the conversion of creatine phosphate to creatinine is 3 times faster than the conversion of creatine to creatinine). It is also possible that the subnormal value of serum creatinine is a consequence of an insufficient supply of creatine during nutritional support of critically ill patients in the ICU. Parenteral nutrition does not contain creatine at all, and enteral nutrition are mostly made from milk, which contains only minimal amounts of creatine. This fact creates an environment for the transformation of critically ill patients into the "position of vegetarians", who have demonstrably lower serum creatinine concentrations and also lower muscle strength than "omnivores".

A number of clinical studies have shown that low serum creatinine on admission are associated with higher mortality in patients admitted to the ICU. However, it is not known whether this finding also apply to patients admitted to the post-ICU care unit. Similarly, it is not known whether nutritional support enriched with creatine can improve the outcome of patients admitted to the ICU or to the post-ICU care units. Creatine is a food supplement with significant ergogenic potential and its beneficial effect in these patients is generally expected. The aim of the study is to contribute to clarifying the above-described uncertainties in the knowledge of this issue. The relationship between subnormal serum creatinine od admission and weaning from mechanical ventilation will be investigated through prospective observation, with the assumption that patients with subnormal creatinine levels will have a prolonged weaning compared to patients with normal creatinine values. The methodology of a prospective double-blind, placebo-controlled, randomized clinical trial will be used to investigate the benefit of supplementing nutritional support with creatine in a group of patients with subnormal creatinine value on admission. It is assumed that this procedure will be associated with a reduction in the need for ventilatory support and a better outcome compared to patients who will not receive creatine.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients <18 years of age
  • Patients admitted to post-ICU care units at Chronicare Group a.s. in the Czech Republic within 12 months

Exclusion criteria

  • Patients who are unlikely to be weaned from ventilatory support.
  • Patients in palliative care or with a survival probability of <3 months
  • Patients with advanced malignancy
  • Patients with a history of chronic kidney disease
  • Patients with a history of chronic liver disease
  • Patients with supranormal serum creatinine on admission to the post-ICU care unit
  • Patients who refused to sign the Informed Consent with participation in the study.

Treatment and study plan

Dietary supplement creatine

Dietary Supplement

Dietary supplement creatine. The dosage of creatine will be as follows: for the first 7 days after enrolment, the daily dose will be 2x5g. From days 8 to 21, the daily dose will be 1x5g. The substance will be administered orally or through a nasogastric tube.

Dietary Supplement - Placebo

Dietary Supplement

Dietary supplement polydextrose as a placebo. The dosage of placebo will be as follows: for the first 7 days after enrolment, the daily dose will be 2x5g. From days 8 to 21, the daily dose will be 1x5g. The substance will be administered orally or through a nasogastric tube.

No intervention

Other

Patients in Group 1 will serve as controls and will receive no intervention, only standard care.

Primary outcomes

  1. Ventilator-free hours

    Time frame: 21 days

    The primary endpoint of the study will be the "ventilator-free hours", i.e. the total number of hours that the patient was without ventilator support

Secondary outcomes

  1. Incidence of newly recorded infections

    Time frame: 21 days

    Secondary endpoints of the study will also include monitoring the incidence of newly recorded infections, assessing the level of respiratory effort with the use of a cough assist. The level of respiratory strength when using a cough assist will be assessed by measur-ing "Peak Cough Flow" directly on the device used. This will be assessed on study days 1, 7, 14, and 21 after enrolment. A newly recorded infection will be considered a situation where it was necessary to start a new antibiotic treatment or a situation where it was necessary to escalate an al-ready ongoing antibiotic treatment. The frequency of occurrence of these situations will be assessed daily over a 21-day period.

  2. Changes in self-sufficiency

    Time frame: 21 days

    Changes in self-sufficiency will be assessed using the Barthel scale.

  3. Changes in cognitive status

    Time frame: 21 days

    Changes in cognitive status will be assessed using the "ChroniCare Cognitive Orientation Tool (CC-COT)", a non-standardized tool for the assessment of cognition in patients with limited verbal and non-verbal communication. The tool is a modification of the Mini-Cog test that has been adapted for the conditions of the post-ICU care in patients with tracheostomy, ventilator support, and limited verbal and non-verbal communication.

  4. Changes in muscle strength

    Time frame: 21 days

    Changes in muscle strength will be assessed using a hand-held dynamometer.

  5. Creatine tolerance

    Time frame: 21 days

    To assess creatine tolerance, the incidence of gastrointestinal discomfort (bloating or diarrhoea) will be monitored daily for 21 days. The incidence of creatinine and cystatin C elevations into the supranormal range will also be monitored on days 7, 14, and 21 after study enrolment.

Other outcomes

  1. 28-day mortality

    Time frame: 28 days

    28-day mortality will be monitored as a tertiary outcome measure.

Study contacts

Contact information is provided by the study sponsor or research team.

Jiří Hynčica

CONTACT

[email protected]

0042059737 ext. 2587

Sponsors and collaborators

Lead sponsor

University Hospital Ostrava

Other

Registry information

Acronym: SECRET-VENT

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Sep 16, 2025
Registry last updated
Feb 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.